Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd announced that a penalty of INR 3,59,10,000 imposed on its wholly-owned subsidiary, Maxcure Nutravedics Limited, by the Deputy Commissioner of State Tax, Gujarat, has been set aside. The order was passed by the First Appellate Authority, Ahmedabad, on July 3rd, 2026. The penalty was originally imposed due to an incorrect shipping address entered on an invoice and e-way bill in October 2025. This decision will have no financial impact on Akums Drugs and Pharmaceuticals Ltd.

Akums Drugs and Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut from July 1st, 2026, and will reopen 48 hours after the declaration of the un-audited financial results for the quarter ending June 30th, 2026. The company will announce the date of the board meeting to approve these results in due course.

Akums Drugs and Pharmaceuticals Ltd has issued a notice and integrated annual report for FY 2025-26 to members who have not registered their email IDs. This communication provides web-links to access the full report as per SEBI regulations. The company also reminded members to update their contact and bank details for efficient communication and dividend credit. The 22nd Annual General Meeting is scheduled for July 10, 2026, via Video Conferencing.

Akums Drugs and Pharmaceuticals Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, along with an Independent Assurance Statement from BDO India Services Private Limited. The report, which is part of the Integrated Annual Report, details the company's business activities, including manufacturing of pharma products and allied services, which accounted for 90% of its turnover. Key activities include CDMO services (79.95%), API manufacturing (4.23%), Domestic Branded Formulations (10.25%), International Branded Formulations (3.29%), and Trade Generics (2.29%). The company operates 14 plants and 5 offices nationally, serving a diverse customer base including pharmaceutical and FMCG companies, and healthcare providers, with exports contributing 4.4% to turnover.

Akums Drugs and Pharmaceuticals Ltd has filed its Integrated Annual Report for FY 2025-26, along with the notice for its 22nd Annual General Meeting. The AGM is scheduled for Friday, July 10, 2026, at 11:00 A.M. (IST) through Video Conferencing. The report details the company's focus on manufacturing excellence, complex formulations, and global expansion. Key initiatives include a joint venture with the Government of Zambia to establish a pharmaceutical manufacturing plant and successful completion of audits for entry into European markets.

Akums Drugs and Pharmaceuticals Ltd announced its 22nd Annual General Meeting (AGM) to be held on Friday, July 10, 2026, at 11:00 A.M. (IST) via video conferencing. The agenda includes adopting audited standalone and consolidated financial statements for FY26. The Board has recommended a final dividend of Re. 1/- and a special dividend of Rs. 2/-, totaling Rs. 3/- per equity share (@150%) for FY26, with a record date of July 03, 2026. Other key items include the re-appointment of Mr. Sanjay Sinha as a Director and the ratification of the Cost Auditors' remuneration for FY26-27 at Rs. 3,00,000/- plus taxes. The meeting will also consider revising the remuneration of Mr. Sanjeev Jain, Managing Director.

Akums Drugs and Pharmaceuticals Ltd reports that its wholly-owned subsidiaries, Maxcure Nutravedics Limited, Pure and Cure Healthcare Private Limited, Malik Lifesciences Private Limited, and Nicholas Healthcare Limited, received assessment orders under Section 158BC of the Income Tax Act, 1961. The orders pertain to the block period from April 1, 2018, to March 12, 2025. The subsidiaries received demands of ₹15,23,84,730, ₹5,77,12,428, ₹80,49,432, and ₹44,97,058 respectively, due to disallowance of expenditures under Section 37(1) of the Act. The companies plan to appeal the orders, citing they are defendable and may not have a material financial impact.

Akums Drugs and Pharmaceuticals Ltd and its subsidiary Akumentis Healthcare Ltd received assessment orders from the Income Tax Department under Section 158BC of the Income Tax Act, 1961, for the block period from April 1, 2018, to March 12, 2025. Akums received a demand of ₹60,09,22,342, while Akumentis received a demand of ₹73,66,10,238, both due to disallowance of expenditures under Section 37(1) of the Act. Both companies plan to appeal the orders, citing that the demands are not sustainable and defendable.

Akums Drugs and Pharmaceuticals Ltd announced the resumption of 100% operations at its Haridwar manufacturing sites, effective May 18, 2026, following a four-day disruption. The disruption resulted in a delayed supply of approximately ₹20 Cr. The company anticipates recovering the production loss in the coming weeks and will not be filing any insurance claims related to the disruption.

Akums Drugs and Pharmaceuticals Ltd reports that manufacturing operations at its affected sites in Haridwar and its subsidiaries have resumed at over 70% capacity as of May 16, 2026, following an industry-wide disruption triggered by a review of minimum wages by state authorities in Uttarakhand. The company anticipates progressive improvement in productivity levels, with local authorities coordinating to restore normalcy. The company has industrial insurance to cover the loss of production.